Literature DB >> 12815135

Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Didier Lardinois1, Walter Weder, Thomas F Hany, Ehab M Kamel, Stephan Korom, Burkhardt Seifert, Gustav K von Schulthess, Hans C Steinert.   

Abstract

BACKGROUND: We compared the diagnostic accuracy of integrated positron-emission tomography (PET) and computed tomography (CT) with that of CT alone, that of PET alone, and that of conventional visual correlation of PET and CT in determining the stage of disease in non-small-cell lung cancer.
METHODS: In a prospective study, integrated PET-CT was performed in 50 patients with proven or suspected non-small-cell lung cancer. CT and PET alone, visually correlated PET and CT, and integrated PET-CT were evaluated separately, and a tumor-node-metastasis (TNM) stage was assigned on the basis of image analysis. Nodal stations were identified according to the mapping system of the American Thoracic Society. The standard of reference was histopathological assessment of tumor stage and node stage. Extrathoracic metastases were confirmed histopathologically or by at least one other imaging method. A paired sign test was used to compare integrated PET-CT with the other imaging methods.
RESULTS: Integrated PET-CT provided additional information in 20 of 49 patients (41 percent), beyond that provided by conventional visual correlation of PET and CT. Integrated PET-CT had better diagnostic accuracy than the other imaging methods. Tumor staging was significantly more accurate with integrated PET-CT than with CT alone (P=0.001), PET alone (P<0.001), or visual correlation of PET and CT (P=0.013); node staging was also significantly more accurate with integrated PET-CT than with PET alone (P=0.013). In metastasis staging, integrated PET-CT increased the diagnostic certainty in two of eight patients.
CONCLUSIONS: Integrated PET-CT improves the diagnostic accuracy of the staging of non-small-cell lung cancer. Copyright 2003 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12815135     DOI: 10.1056/NEJMoa022136

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  284 in total

1.  PET/CT in lung cancer: Influence of contrast medium on quantitative and clinical assessment.

Authors:  Florian F Behrendt; Yavuz Temur; Frederik A Verburg; Moritz Palmowski; Thomas Krohn; Hubertus Pietsch; Christiane K Kuhl; Felix M Mottaghy
Journal:  Eur Radiol       Date:  2012-06-04       Impact factor: 5.315

2.  Do we need randomised trials to evaluate diagnostic procedures? For.

Authors:  H Van Tinteren; O S Hoekstra; M Boers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-29       Impact factor: 9.236

Review 3.  PET/CT: a new imaging technology in nuclear medicine.

Authors:  Heiko Schöder; Yusuf E Erdi; Steven M Larson; Henry W D Yeung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-05       Impact factor: 9.236

Review 4.  PET/CT and breast cancer.

Authors:  Barbara Zangheri; Cristina Messa; Maria Picchio; Luigi Gianolli; Claudio Landoni; Ferruccio Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-05       Impact factor: 9.236

5.  Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT?

Authors:  Patrick Reinartz; Franz-Josef Wieres; Wolfram Schneider; Alexander Schur; Ulrich Buell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-10       Impact factor: 9.236

Review 6.  Molecular imaging for personalized cancer care.

Authors:  Moritz F Kircher; Hedvig Hricak; Steven M Larson
Journal:  Mol Oncol       Date:  2012-03-10       Impact factor: 6.603

7.  A nephrotoxicity-free, iron-based contrast agent for magnetic resonance imaging of tumors.

Authors:  Xiangdong Xue; Ruonan Bo; Haijing Qu; Bei Jia; Wenwu Xiao; Ye Yuan; Natalia Vapniarsky; Aaron Lindstrom; Hao Wu; Dalin Zhang; Longmeng Li; Marina Ricci; Zhao Ma; Zheng Zhu; Tzu-Yin Lin; Angelique Y Louie; Yuanpei Li
Journal:  Biomaterials       Date:  2020-07-15       Impact factor: 12.479

8.  PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences.

Authors:  Bernd Klaeser; Michel D Mueller; Ralph A Schmid; Carlos Guevara; Thomas Krause; Jakub Wiskirchen
Journal:  Eur Radiol       Date:  2009-02-24       Impact factor: 5.315

9.  Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients.

Authors:  Alexander J Antoniou; Charles Marcus; Abdel K Tahari; Richard L Wahl; Rathan M Subramaniam
Journal:  J Nucl Med       Date:  2014-04-28       Impact factor: 10.057

10.  Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?

Authors:  Markus Selzner; Thomas F Hany; Peer Wildbrett; Lucas McCormack; Zakiyah Kadry; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.